ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Poliovirus Vaccine, Inactivated

Also written as “sIPV”, “IPV” and “Poliorix™”.

Its studies are mostly in Poliomyelitis · Gastroenteritis · Streptococcal Infections · Tetanus, led by 7 companies.

Drug pagePoliovirus Vaccine, Inactivated: every studyMany companies study it; this page follows only the 16 they lead. All 27 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 19, 200716 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only50 open or runningphase 3since Oct 19, 2007Oct 19, 2007none ahead
Sinovac Biotech41 open or runningphase 4since Jan 29, 2024May 4, 2018none ahead
Beijing Minhai Biotechnologyits history only20 open or runningphase 3since Dec 12, 2024Dec 12, 2024none ahead
Johnson & Johnsonits history only20 open or runningphase 2since Jun 12, 2018Jan 24, 2017none ahead
E-MO Biologyits history only10 open or runningphase 4since Nov 16, 2020Nov 16, 2020none ahead
Sinopharmits history only10 open or runningphase 4since Aug 8, 2019Aug 8, 2019none ahead
Takedaits history only10 open or runningphase 2since Mar 24, 2017Mar 24, 2017none ahead

Also a collaborator on its studies: Beijing Institute of Biological Products.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sinovac Biotech only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 4, 2018First study: phase 3 study in PoliomyelitisFirst studyNCT03526978 · 1,200 enrolled · China
  2. Jan 29, 2024Phase 4 study in PoliomyelitisNCT06346834 · 200 enrolled · China
  3. May 29, 2024Phase 4 study in PoliomyelitisNCT06442449 · 889 enrolled · China
  4. Apr 22, 2025Phase 4 study in PoliomyelitisNCT07354269 · 180 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine consisting of inactivated poliovirus (IPV) types 1,2 and 3, with active immunizing activity against poliomyelitis”NCIt, by rule

Studies

All 4 Sinovac Biotech leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07354269Poliomyelitis · China4RecruitingApr 11, 2026180
NCT06442449Poliomyelitis · China4CompletedSep 10, 2025889
NCT06346834Poliomyelitis · China4CompletedSep 6, 2024200
NCT03526978Poliomyelitis · China3CompletedOct 18, 20171,200

How it is read

Names in the registry

  • “sIPV”, 6 entries
  • “IPV”, 3 entries
  • “Poliorix™”, 2 entries
  • “Poliorix”, 2 entries
  • “sIPV+bOPV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.